Skip to main content
Premium Trial:

Request an Annual Quote

Precision BioSciences Denies Infringing Cellectis Patents

NEW YORK (GenomeWeb News) – Precision BioSciences today responded to a lawsuit filed last week against it by Cellectis, which claims the Research Triangle Park, NC-based firm is infringing two Cellectis patents that cover meganuclease recombination systems, by saying that “no such infringement has occurred.”
 
Cellectis filed the suit last week in the US District Court for the Eastern District of North Carolina Western Division. The French firm alleged that Precision Bio infringed US Patent Nos. 7,309,605 and 6,610,545 — both of which are entitled “Nucleotide Sequence Encoding the Enzyme I-SceI and the Uses Thereof.”
 
The patents describe methods of using Group I intron encoded endonucleases to produce a site-directed double-stranded break in DNA for promotion of genetic recombination in organisms. Cellectis holds exclusive rights to the patents, which are owned by Institut Pasteur and Universite Pierre et Marie Curie.
 
According to Cellectis’ complaint, “Precision has been and is making Group I intron encoded endonucleases that are specifically intended for use by others in methods for inducing at least one site-directed double-stranded break in the DNA of an organism.”
 
“It is clear that our next-generation genome engineering technology is demonstrably distinct from the dated technology covered by Cellectis’ patents,” Precision Bio CEO Matthew Kane said in a statement. “This lawsuit appears to stem from a fundamental misunderstanding of Precision’s DNE technology and how it is employed.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.